Please login to the form below

Not currently logged in
Email:
Password:

CHMP recommends Erbitux

Merck Serono has announced that the Committee for Medicinal Products for Human Use has given a positive recommendation for an application to extend the uses of its cancer drug, Erbitux
Merck Serono has announced that the Committee for Medicinal Products for Human Use (CHMP) has given a positive recommendation for an application to extend the uses of its cancer drug, Erbitux.

The drug has already been approved for the treatment of colorectal cancer (CRC) in Europe and was licensed for use on the market in June 2004. Merck and Serono hope to extend the use of Erbitux to include the treatment of metastatic colorectal cancer (mCRC) with KRAS wild-type tumours, and is to be used in combination with chemotherapy.

The company, a division of global pharmaceutical manufacturer and developer, Merck, said that the scientific committee at the European Medicines Agency (EMEA) also gave its backing for the application.

Dr Wolfgang Wein, executive vice-president of oncology at Merck, said: "The positive opinion from the CHMP is an important step forward in the management of CRC and a step closer to tailored therapy for cancer patients."

30th May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics